Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the efficacy and safety of olanzapine combined with fosaprepitant, ondansetron and dexamethasone compared with placebo combined with fosaprepitant, ondansetron and dexamethasone in the prevention of nausea and vomiting in germ-cell tumors receiving 5-day cisplatin chemotherapy


Clinical Trial Description

This is a prospective, randomized, double-blind, placebo-controlled, cross-over Phase III clinical study. A total of 75 patients were enrolled in two sequential treatment groups (olanzapine-placebo and placebo-Olanzapine). (1) The screening process begins after the patient signs the written informed consent. (2) Patients were randomly divided into control group (placebo) and experimental group (olanzapine). (3) Patients' effectiveness from the beginning of chemotherapy drug infusion (0 h on day 1) to day 10 (approximately 240 h) was monitored by patients' diary from 2 to 10 days after chemotherapy, in which patients should report episodes of vomiting in the previous 24 hours, use of remedial therapy, and assessment of daily nausea. Any episodes of vomiting or retching, as well as the time and date of use of rescue medications, should also be recorded. At days 2 to 6, patients were assessed on the visual analog scale (VAS) for the previous 24 hours. (4) The Hospital Anxiety and Depression Scale (HADS),and Life Index - Vomiting (FLIE) questionnaire of days 1-10 should be completed immediately after the log is completed on day 10. (5) During the study period, patients may receive "remedial treatment" for nausea or vomiting, and patients requiring remedial treatment are considered to have failed treatment because the primary endpoint is complete remission. However, patients receiving remedial treatment must continue to receive the study drug and complete the diary as directed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05244577
Study type Interventional
Source Sun Yat-sen University
Contact Yanxia Shi, PHD
Phone +8613609058827
Email shiyx@sysucc.org.cn
Status Recruiting
Phase Phase 3
Start date January 18, 2022
Completion date March 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05030077 - Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Phase 2
Recruiting NCT04848454 - Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Phase 2
Completed NCT03079427 - Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Phase 2
Completed NCT03639168 - Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) Phase 2
Recruiting NCT03919552 - Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma Phase 3
Not yet recruiting NCT01285674 - Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin. N/A
Recruiting NCT03373019 - Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase 2